Pulse Biosciences (NASDAQ:PLSE) Rating Lowered to Sell at ValuEngine

Pulse Biosciences (NASDAQ:PLSE) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Monday, ValuEngine reports.

Separately, BidaskClub raised shares of Pulse Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, September 26th.

Shares of NASDAQ:PLSE opened at $15.97 on Monday. Pulse Biosciences has a 12 month low of $8.60 and a 12 month high of $19.77. The company’s 50-day moving average price is $14.67 and its two-hundred day moving average price is $13.38. The company has a quick ratio of 12.92, a current ratio of 12.92 and a debt-to-equity ratio of 0.07. The firm has a market cap of $326.09 million, a P/E ratio of -7.26 and a beta of 1.88.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, equities analysts predict that Pulse Biosciences will post -2.29 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC acquired a new position in Pulse Biosciences during the 2nd quarter valued at about $55,000. Bank of Montreal Can raised its position in shares of Pulse Biosciences by 15.0% in the 2nd quarter. Bank of Montreal Can now owns 8,053 shares of the company’s stock valued at $106,000 after acquiring an additional 1,053 shares during the period. Westside Investment Management Inc. acquired a new stake in shares of Pulse Biosciences in the 2nd quarter valued at approximately $5,074,000. Charles Schwab Investment Management Inc. raised its position in shares of Pulse Biosciences by 7.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,993 shares of the company’s stock valued at $357,000 after acquiring an additional 1,853 shares during the period. Finally, Griffin Asset Management Inc. raised its position in shares of Pulse Biosciences by 11.6% in the 2nd quarter. Griffin Asset Management Inc. now owns 57,315 shares of the company’s stock valued at $757,000 after acquiring an additional 5,955 shares during the period. Institutional investors own 9.88% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.

Featured Story: What is a Tariff?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.